Carcinoma of the body and tail of the pancreas

https://doi.org/10.1016/S0002-9610(05)80641-5Get rights and content

Recently, several institutions have reported improved results in the treatment of patients with carcinoma of the head of the pancreas. In an attempt to determine whether similar trends could be demonstrated for patients with carcinoma of the body and tail of the pancreas, the records of all 113 patients with an adenocarcinoma of the body or tail of the pancreas treated at The Johns Hopkins Hospital between 1972 and 1989 were reviewed. The patients were divided into two groups: those diagnosed between 1972 and 1982 (41 patients) and those between 1983 and 1989 (72 patients). No significant differences in tumor stage were observed between the two groups. The proportion of patients who underwent surgery decreased from 68% to 47% (p=0.02). The number of patients who had bypass operations (15% versus 17%) or pancreatic resection (5% versus 10%) was similar in the two groups, but the proportion of patients who underwent exploratory laparotomy with biopsy only decreased from 49% to 21% (p=0.002). The postoperative 30-day mortality (7% versus 3%), postoperative morbidity (18% versus 21%), median survival (4 months versus 3 months), and the 1-year survival (8% versus 9%) did not differ significantly between the two groups. One patient survived for 6 years after resection, and another patient is still alive 3 years after resection. Thus, unlike adenocarcinoma of the head of the pancreas, it appears that treatment results for patients with adenocarcinoma of the body or tail of the pancreas have not improved in recent years, the only change being a decreased need for exploratory laparotomy with biopsy only.

References (14)

There are more references available in the full text version of this article.

Cited by (78)

  • Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma

    2015, Seminars in Oncology
    Citation Excerpt :

    Interestingly, 86% of patients enrolled in the study had pancreatic head tumors and the study was mainly powered to analyze the survival among these patients. This distinction was made because investigators reasoned that patients with resected pancreatic body or tail tumors generally have different clinical presentations and operations, as well as an overall worse prognosis compared to those with head tumors.15,16 Therefore, by using the key primary endpoint of overall survival for patients with pancreatic head tumors, the investigators reported a median survival of.

  • Solid Tumors of the Body and Tail of the Pancreas

    2010, Surgical Clinics of North America
    Citation Excerpt :

    Mortality rates are reported at 0% to 4%. Morbidity is reported at to 23% to 49%.13–20,34 In 35% to 39% of patients, an en bloc resection to include locally involved structures may be necessary (including portal venous confluence, stomach, colon, left kidney, or left adrenal gland).

  • Cancer of the Pancreas

    2010, Leibel and Phillips Textbook of Radiation Oncology, Third Edition
View all citing articles on Scopus
1

From the Department of Surgery, The Johns Hopkins Medical Institutions Baltimore, Maryland.

2

From the Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland.

View full text